Email ID
Password
Sign me in automatically next time
Basilea and Astellas shake hands on antifungal deal worth up to CHF550 million
24 February 2010
Christopher Spillane

Swiss biotech company Basilea Pharmaceutica has agreed a worldwide licensing deal with Astellas Pharma for its Phase III antifungal isavuconazole.

Basilea will receive CHF75 million ($69.4 million) up front and up to CHF478 million in development and sales milestones as well as...



Please Login to read the full article.
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK Promote your vacancy here
© 2012 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36